المؤلفون: Wesley JD; Type 1 Diabetes & Kidney Disease, Global Drug Discovery, Novo Nordisk Research Center Seattle, Inc., Seattle, Washington, USA., Pagni PP; Type 1 Diabetes & Kidney Disease, Global Drug Discovery, Novo Nordisk Research Center Seattle, Inc., Seattle, Washington, USA., Bergholdt R; Type 1 Diabetes & Functional Insulins, Clinical Drug Development., Kreiner FF; Global Chief Medical Office, Novo Nordisk A/S, Søborg, Denmark., von Herrath M; Global Chief Medical Office, Novo Nordisk A/S, Søborg, Denmark.; Type 1 Diabetes Center, The La Jolla Institute for Immunology, La Jolla, California, USA.

المصدر: Current opinion in endocrinology, diabetes, and obesity [Curr Opin Endocrinol Diabetes Obes] 2022 Aug 01; Vol. 29 (4), pp. 379-385. Date of Electronic Publication: 2022 Jul 02.

نوع المنشور: Journal Article; Review; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Lippincott, Williams & Wilkins Country of Publication: England NLM ID: 101308636 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1752-2978 (Electronic) Linking ISSN: 1752296X NLM ISO Abbreviation: Curr Opin Endocrinol Diabetes Obes Subsets: MEDLINE

مواضيع طبية MeSH: Diabetes Mellitus, Type 1* , Insulin-Secreting Cells*, Autoantigens ; Humans ; Immune Tolerance ; Immunotherapy/methods

المؤلفون: Pagni PP; Type 1 Diabetes & Kidney Disease, Global Drug Discovery, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, U.S.A., Chaplin J; Type 1 Diabetes & Kidney Disease, Global Drug Discovery, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, U.S.A., Wijaranakula M; Type 1 Diabetes & Kidney Disease, Global Drug Discovery, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, U.S.A., Wesley JD; Type 1 Diabetes & Kidney Disease, Global Drug Discovery, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, U.S.A., Granger J; Type 1 Diabetes & Kidney Disease, Global Drug Discovery, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, U.S.A., Cracraft J; Type 1 Diabetes & Kidney Disease, Global Drug Discovery, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, U.S.A., O'Brien C; Type 1 Diabetes & Kidney Disease, Global Drug Discovery, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, U.S.A., Perdue N; Type 1 Diabetes & Kidney Disease, Global Drug Discovery, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, U.S.A., Kumar V; Type 1 Diabetes & Kidney Disease, Global Drug Discovery, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, U.S.A., Li S; Type 1 Diabetes & Kidney Disease, Global Drug Discovery, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, U.S.A., Ratliff SS; La Jolla Institute for Immunology, La Jolla, CA, USA., Roach A; Type 1 Diabetes & Kidney Disease, Global Drug Discovery, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, U.S.A., Misquith A; Discovery Biologics, Global Research Technologies, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, U.S.A., Chan CL; Discovery Biologics, Global Research Technologies, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, U.S.A., Coppieters K; Project and Alliance Management, Global Drug Discovery, Novo Nordisk A/S, Måløv, Denmark., von Herrath M; La Jolla Institute for Immunology, La Jolla, CA, USA.; Global Chief Medical Office, Novo Nordisk A/S, Søborg, Denmark.

المصدر: Diabetes [Diabetes] 2021 Aug 13. Date of Electronic Publication: 2021 Aug 13.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Diabetes Association Country of Publication: United States NLM ID: 0372763 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1939-327X (Electronic) Linking ISSN: 00121797 NLM ISO Abbreviation: Diabetes Subsets: MEDLINE

المؤلفون: Pagni PP; Type 1 Diabetes & Kidney Disease, Global Drug Discovery, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, U.S.A., Chaplin J; Type 1 Diabetes & Kidney Disease, Global Drug Discovery, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, U.S.A., Wijaranakula M; Type 1 Diabetes & Kidney Disease, Global Drug Discovery, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, U.S.A., Wesley JD; Type 1 Diabetes & Kidney Disease, Global Drug Discovery, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, U.S.A., Granger J; Type 1 Diabetes & Kidney Disease, Global Drug Discovery, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, U.S.A., Cracraft J; Type 1 Diabetes & Kidney Disease, Global Drug Discovery, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, U.S.A., O'Brien C; Type 1 Diabetes & Kidney Disease, Global Drug Discovery, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, U.S.A., Perdue N; Type 1 Diabetes & Kidney Disease, Global Drug Discovery, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, U.S.A., Kumar V; Type 1 Diabetes & Kidney Disease, Global Drug Discovery, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, U.S.A., Li S; Type 1 Diabetes & Kidney Disease, Global Drug Discovery, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, U.S.A., Ratliff SS; La Jolla Institute for Immunology, La Jolla, CA, USA., Roach A; Type 1 Diabetes & Kidney Disease, Global Drug Discovery, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, U.S.A., Misquith A; Discovery Biologics, Global Research Technologies, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, U.S.A., Chan CL; Discovery Biologics, Global Research Technologies, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, U.S.A., Coppieters K; Project and Alliance Management, Global Drug Discovery, Novo Nordisk A/S, Måløv, Denmark., von Herrath M; La Jolla Institute for Immunology, La Jolla, CA, USA matthias@lji.org.; Global Chief Medical Office, Novo Nordisk A/S, Søborg, Denmark.

المصدر: Diabetes [Diabetes] 2021 Aug 13. Date of Electronic Publication: 2021 Aug 13.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Diabetes Association Country of Publication: United States NLM ID: 0372763 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1939-327X (Electronic) Linking ISSN: 00121797 NLM ISO Abbreviation: Diabetes Subsets: MEDLINE

المؤلفون: Chodaczek G; Type 1 Diabetes Center, La Jolla Institute for Immunology, La Jolla, CA, USA; Bioimaging Laboratory, Łukasiewicz Research Network - PORT Polish Center for Technology Development, Wroclaw, Poland. Electronic address: grzegorz.chodaczek@port.lukasiewicz.gov.pl., Pagni PP; Type 1 Diabetes Center, La Jolla Institute for Immunology, La Jolla, CA, USA., Christoffersson G; Type 1 Diabetes Center, La Jolla Institute for Immunology, La Jolla, CA, USA; Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden., Ratliff SS; Type 1 Diabetes Center, La Jolla Institute for Immunology, La Jolla, CA, USA., Toporkiewicz M; Bioimaging Laboratory, Łukasiewicz Research Network - PORT Polish Center for Technology Development, Wroclaw, Poland., Wegrzyn AS; Bioimaging Laboratory, Łukasiewicz Research Network - PORT Polish Center for Technology Development, Wroclaw, Poland., von Herrath M; Type 1 Diabetes Center, La Jolla Institute for Immunology, La Jolla, CA, USA.

المصدر: Journal of autoimmunity [J Autoimmun] 2021 Jan; Vol. 116, pp. 102563. Date of Electronic Publication: 2020 Nov 12.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Academic Press Country of Publication: England NLM ID: 8812164 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-9157 (Electronic) Linking ISSN: 08968411 NLM ISO Abbreviation: J Autoimmun Subsets: MEDLINE

مواضيع طبية MeSH: Cell Movement/*immunology , T-Lymphocytes, Regulatory/*immunology , Toll-Like Receptor 2/*immunology , Toll-Like Receptor 7/*immunology, Animals ; Cell Movement/drug effects ; Cells, Cultured ; Imidazoles/pharmacology ; Mice, Inbred C57BL ; Microscopy, Confocal/methods ; T-Lymphocytes, Regulatory/cytology ; T-Lymphocytes, Regulatory/drug effects ; Toll-Like Receptor 2/agonists ; Toll-Like Receptor 7/agonists ; Mice

المؤلفون: Pagni PP; Novo Nordisk Research Center, Seattle, WA, USA., Wolf A; Novo Nordisk Research Center, Seattle, WA, USA., Lo Conte M; Novo Nordisk Research Center, Seattle, WA, USA., Yeh R; Novo Nordisk Research Center, Seattle, WA, USA., Fu G; Novo Nordisk Research Center, Seattle, WA, USA., Liu F; Novo Nordisk Research Center, Seattle, WA, USA., von Herrath M; Novo Nordisk Research Center, Seattle, WA, USA., Coppieters K; Novo Nordisk A/S Research Projects, Novo Nordisk Park, DK-2760, Måløv, Denmark. kncp@novonordisk.com.

المصدر: Diabetologia [Diabetologia] 2019 Sep; Vol. 62 (9), pp. 1727-1729. Date of Electronic Publication: 2019 May 17.

نوع المنشور: Letter; Comment

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0006777 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0428 (Electronic) Linking ISSN: 0012186X NLM ISO Abbreviation: Diabetologia Subsets: MEDLINE

مواضيع طبية MeSH: Diabetes Mellitus, Type 1*, Animals ; CD40 Antigens ; CD40 Ligand ; Mice ; Mice, Inbred NOD ; Peptides

المؤلفون: von Herrath M; Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA. Electronic address: mtvh@novonordisk.com., Pagni PP; Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA., Grove K; Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA., Christoffersson G; Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden., Tang-Christensen M; Novo Nordisk A/S, Måløv, Denmark., Karlsen AE; Novo Nordisk A/S, Måløv, Denmark., Petersen JS; Novo Nordisk A/S, Måløv, Denmark.

المصدر: Cell metabolism [Cell Metab] 2019 Apr 02; Vol. 29 (4), pp. 795-802. Date of Electronic Publication: 2019 Mar 14.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101233170 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1932-7420 (Electronic) Linking ISSN: 15504131 NLM ISO Abbreviation: Cell Metab Subsets: MEDLINE

مواضيع طبية MeSH: Diabetes Mellitus/*metabolism, Animals ; Case-Control Studies ; Humans ; Reproducibility of Results

المؤلفون: Rydén AK; Type 1 Diabetes R&D Center, Novo Nordisk Inc., Seattle, WA, USA; Pacific Northwest Diabetes Research Institute, Seattle, WA, USA., Perdue NR; Type 1 Diabetes R&D Center, Novo Nordisk Inc., Seattle, WA, USA., Pagni PP; Type 1 Diabetes R&D Center, Novo Nordisk Inc., Seattle, WA, USA., Gibson CB; Type 1 Diabetes R&D Center, Novo Nordisk Inc., Seattle, WA, USA., Ratliff SS; Type 1 Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA., Kirk RK; Department of Histology and Imaging, Novo Nordisk A/S, Måløv, Denmark., Friesen TJ; Type 1 Diabetes R&D Center, Novo Nordisk Inc., Seattle, WA, USA., Haase C; Department of Immunopharmacology, Novo Nordisk A/S, Måløv, Denmark., Coppieters K; Type 1 Diabetes R&D Center, Novo Nordisk Inc., Seattle, WA, USA., von Herrath MG; Type 1 Diabetes R&D Center, Novo Nordisk Inc., Seattle, WA, USA., Boursalian TE; Type 1 Diabetes R&D Center, Novo Nordisk Inc., Seattle, WA, USA. Electronic address: tbl@novonordisk.com.

المصدر: Journal of autoimmunity [J Autoimmun] 2017 Nov; Vol. 84, pp. 65-74. Date of Electronic Publication: 2017 Jul 12.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Academic Press Country of Publication: England NLM ID: 8812164 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-9157 (Electronic) Linking ISSN: 08968411 NLM ISO Abbreviation: J Autoimmun Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal/*therapeutic use , Diabetes Mellitus, Type 1/*therapy , Hyperglycemia/*therapy , Immunotherapy/*methods , Insulin-Secreting Cells/*immunology , Interleukins/*immunology , Liraglutide/*therapeutic use, Animals ; Diabetes Mellitus, Type 1/immunology ; Disease Models, Animal ; Drug Therapy, Combination ; Female ; Humans ; Hyperglycemia/immunology ; Insulin/genetics ; Insulin/metabolism ; Mice ; Mice, Inbred NOD ; Mice, Transgenic

المؤلفون: Grönholm J; Molecular Development of the Immune System Section, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases (NIAID) and Clinical Genomics Program, NIAID, National Institutes of Health, Building 10, Room 11D14, 10 Center Drive, Bethesda, MD, 20814, USA., Pagni PP; Novo Nordisk Type 1 Diabetes Center, Novo Nordisk Research Center, Seattle, WA, USA.; La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA., Pham MN; Novo Nordisk Type 1 Diabetes Center, Novo Nordisk Research Center, Seattle, WA, USA., Gibson CB; Novo Nordisk Type 1 Diabetes Center, Novo Nordisk Research Center, Seattle, WA, USA., Macomber PF; Wellstat Diagnostics, Gaithersburg, MD, USA., Vela JL; Novo Nordisk Type 1 Diabetes Center, Novo Nordisk Research Center, Seattle, WA, USA., von Herrath M; Novo Nordisk Type 1 Diabetes Center, Novo Nordisk Research Center, Seattle, WA, USA., Lenardo MJ; Molecular Development of the Immune System Section, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases (NIAID) and Clinical Genomics Program, NIAID, National Institutes of Health, Building 10, Room 11D14, 10 Center Drive, Bethesda, MD, 20814, USA. lenardo@nih.gov.

المصدر: Diabetologia [Diabetologia] 2017 Aug; Vol. 60 (8), pp. 1475-1482. Date of Electronic Publication: 2017 Apr 28.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Intramural

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0006777 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0428 (Electronic) Linking ISSN: 0012186X NLM ISO Abbreviation: Diabetologia Subsets: MEDLINE

مواضيع طبية MeSH: Diabetes Mellitus, Type 1/*immunology , Diabetes Mellitus, Type 1/*prevention & control , Insulin/*therapeutic use, Animals ; Autoantibodies/immunology ; CD4-Positive T-Lymphocytes/metabolism ; Female ; Flow Cytometry ; Hybridomas/metabolism ; Insulin/analogs & derivatives ; Mice ; Mice, Inbred NOD ; Mice, Transgenic

المؤلفون: Gill RG; Departments of Surgery and Immunology, University of Colorado Denver, Aurora, CO ronald.gill@ucdenver.edu., Pagni PP; La Jolla Institute for Allergy and Immunology, La Jolla, CA., Kupfer T; Departments of Surgery and Immunology, University of Colorado Denver, Aurora, CO., Wasserfall CH; Department of Pathology, University of Florida, Gainesville, FL., Deng S; Yale University School of Medicine, New Haven, CT., Posgai A; Department of Pathology, University of Florida, Gainesville, FL., Manenkova Y; La Jolla Institute for Allergy and Immunology, La Jolla, CA., Bel Hani A; La Jolla Institute for Allergy and Immunology, La Jolla, CA., Straub L; Immune Tolerance Network, University of California, San Francisco, San Francisco, CA., Bernstein P; Immune Tolerance Network, Bethesda, MD., Atkinson MA; Department of Pathology, University of Florida, Gainesville, FL., Herold KC; Yale University School of Medicine, New Haven, CT., von Herrath M; La Jolla Institute for Allergy and Immunology, La Jolla, CA., Staeva T; JDRF, New York, NY., Ehlers MR; Immune Tolerance Network, University of California, San Francisco, San Francisco, CA., Nepom GT; Benaroya Research Institute, Seattle, WA.

المصدر: Diabetes [Diabetes] 2016 May; Vol. 65 (5), pp. 1310-6. Date of Electronic Publication: 2015 Dec 30.

نوع المنشور: Comparative Study; Journal Article

بيانات الدورية: Publisher: American Diabetes Association Country of Publication: United States NLM ID: 0372763 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1939-327X (Electronic) Linking ISSN: 00121797 NLM ISO Abbreviation: Diabetes Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal/*administration & dosage , Autoimmune Diseases/*drug therapy , CD3 Complex/*chemistry , Diabetes Mellitus, Type 1/*drug therapy , Insulin/*metabolism , Insulin-Secreting Cells/*drug effects , Interleukin-1beta/*antagonists & inhibitors, Animals ; Antibodies, Monoclonal/chemistry ; Antibodies, Monoclonal/therapeutic use ; Autoimmune Diseases/immunology ; Autoimmune Diseases/metabolism ; Biomedical Research/methods ; CD3 Complex/metabolism ; Diabetes Mellitus, Type 1/immunology ; Diabetes Mellitus, Type 1/metabolism ; Drug Administration Schedule ; Drug Therapy, Combination ; Female ; Immunoglobulin Fab Fragments/administration & dosage ; Immunoglobulin Fab Fragments/chemistry ; Immunoglobulin Fab Fragments/therapeutic use ; Immunotherapy/methods ; Insulin Secretion ; Insulin-Secreting Cells/immunology ; Insulin-Secreting Cells/metabolism ; Interleukin-1 Receptor Accessory Protein/antagonists & inhibitors ; Interleukin-1 Receptor Accessory Protein/metabolism ; Interleukin-1beta/metabolism ; Mice, Inbred NOD ; Multicenter Studies as Topic ; Pilot Projects ; Receptors, Interleukin-1 Type I/antagonists & inhibitors ; Receptors, Interleukin-1 Type I/metabolism ; Recombinant Fusion Proteins/therapeutic use ; Reproducibility of Results ; Research Design ; Specific Pathogen-Free Organisms ; United States

المؤلفون: Pham MN; Type 1 Diabetes R&D Center, Novo Nordisk Research Center, Seattle, WA, USA., Gibson C; Type 1 Diabetes R&D Center, Novo Nordisk Research Center, Seattle, WA, USA., Rydén AK; Type 1 Diabetes R&D Center, Novo Nordisk Research Center, Seattle, WA, USA., Perdue N; Type 1 Diabetes R&D Center, Novo Nordisk Research Center, Seattle, WA, USA., Boursalian TE; Type 1 Diabetes R&D Center, Novo Nordisk Research Center, Seattle, WA, USA., Pagni PP; Type 1 Diabetes R&D Center, Novo Nordisk Research Center, Seattle, WA, USA; Type 1 Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA., Coppieters K; Novo Nordisk A/S, Måløv, Denmark., Skonberg C; Novo Nordisk A/S, Måløv, Denmark., Porsgaard T; Novo Nordisk A/S, Måløv, Denmark., von Herrath M; Type 1 Diabetes R&D Center, Novo Nordisk Research Center, Seattle, WA, USA; Type 1 Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA., Vela JL; Type 1 Diabetes R&D Center, Novo Nordisk Research Center, Seattle, WA, USA. Electronic address: jvl@novonordisk.com.

المصدر: Clinical immunology (Orlando, Fla.) [Clin Immunol] 2016 Mar; Vol. 164, pp. 28-33. Date of Electronic Publication: 2016 Jan 25.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Academic Press Country of Publication: United States NLM ID: 100883537 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-7035 (Electronic) Linking ISSN: 15216616 NLM ISO Abbreviation: Clin Immunol Subsets: MEDLINE

مواضيع طبية MeSH: Diabetes Mellitus, Experimental/*drug therapy , Diabetes Mellitus, Type 1/*drug therapy , Hypoglycemic Agents/*administration & dosage , Insulin/*administration & dosage, Administration, Oral ; Animals ; Antigens/immunology ; Blood Glucose/analysis ; Diabetes Mellitus, Experimental/blood ; Diabetes Mellitus, Type 1/blood ; Female ; Hemocyanins/immunology ; Humans ; Hypersensitivity, Delayed/immunology ; Hypoglycemic Agents/pharmacokinetics ; Hypoglycemic Agents/therapeutic use ; Immune Tolerance ; Insulin/pharmacokinetics ; Insulin/therapeutic use ; Intestinal Mucosa/metabolism ; Male ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Mice, Inbred NOD ; Swine